Cipla.
Indian multi-national pharmaceutical and biotechnology company
Cipla and Qilu ink exclusive deal to sell Keytruda biosimilar in US
Invagen Pharmaceuticals has signed an exclusive US licensing deal with Qilu Pharmaceutical to commercialize QL2107, a Keytruda (pembrolizumab) biosimilar, with Qilu handling development, regulatory work, and supply while Cipla USA drives commercialization. The arrangement underscores Cipla’s strategy to expand its oncology-focused biosimilars portfolio and reduce cancer treatment costs for patients, following multiple collaborations with Chinese manufacturers.
Business · 6 sources · Sep 4, 2026Read it
The journal
Open the journal →The conversation starts in the journal — be the first to post.
About Cipla
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.
Everything about Cipla →- Country
- India
- Headquarters
- Mumbai
- Inception
- 1935
- Website
- http://www.cipla.com